Homepage6160 • HKG
add
BeOne Medicines AG
Vorige slotkoers
$Â 178,90
Dag-range
$Â 181,20 - $Â 185,80
Jaar-range
$Â 115,80 - $Â 229,40
Beurswaarde
293,42Â mld. HKD
Gem. volume
3,54Â mln.
Koers/winst
120,96
Dividendrendement
-
In het nieuws
Financiële informatie
Resultatenrekening
Opbrengst
Netto inkomsten
| (USD) | dec 2025info | Wijziging j-o-j |
|---|---|---|
Opbrengst | 1,50Â mld. | 32,84% |
Bedrijfskosten | 1,17Â mld. | 11,85% |
Netto inkomsten | 66,50Â mln. | 143,79% |
Netto winstmarge | 4,44 | 132,96% |
Winst per aandeel | 0,58 | — |
EBITDA | 219,47Â mln. | 822,86% |
Effectief belastingtarief | 55,44% | — |
Balans
Totale activa
Totale passiva
| (USD) | dec 2025info | Wijziging j-o-j |
|---|---|---|
Contanten en kortetermijnbeleggingen | 4,55Â mld. | 73,08% |
Totale activa | 8,19Â mld. | 38,30% |
Totale passiva | 3,83Â mld. | 47,85% |
Totaal aandelenvermogen | 4,36 mld. | — |
Uitstaande aandelen | 110,94 mln. | — |
Koers-boekwaardeverhouding | 4,55 | — |
Rendement op activa | 5,85% | — |
Rendement op kapitaal | 8,73% | — |
Kasstroom
Nettomutatie in liquide middelen
| (USD) | dec 2025info | Wijziging j-o-j |
|---|---|---|
Netto inkomsten | 66,50Â mln. | 143,79% |
Operationele kasstroom | 417,35Â mln. | 455,28% |
Kasstroom uit beleggingen | -38,34Â mln. | 59,05% |
Kasstroom uit financiering | 96,93Â mln. | 2.243,07% |
Nettomutatie in liquide middelen | 499,10Â mln. | 768,32% |
Vrije kasstroom | 385,44Â mln. | 9.151,22% |
Over
BeOne Medicines, formerly known as BeiGene, Ltd. is a multinational oncology company. It specializes in the development of drugs for cancer treatment.
Founded in 2010 by chief executive officer John V. Oyler and Xiaodong Wang, the company is headquartered in Cambridge, Massachusetts and has locations on six continents, in over 45 countries. BeOne has a large presence in the Chinese market.
BeOne Medicines has developed several medicines, including tislelizumab, a checkpoint inhibitor, and zanubrutinib, a Bruton's tyrosine kinase inhibitor. On 14 November 2024 the company announced its intention to rebrand as BeOne Medicines. BeOne changed its stock ticker to ONC in January 2025 and redomiciled to Basel, Switzerland in May 2025. Wikipedia
Opgericht
28 okt 2010
Website
Werknemers
12.000
